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INVESTIGATION IN STABILITY OF EIGHT SYNTHETIC PIPERAZINES IN 
HUMAN WHOLE BLOOD UNDER VARIOUS STORAGE CONDITIONS OVER 
TIME 
 
TIMOTHY WAN TSUN LAU 
 
ABSTRACT 
 Over the past decade, synthetic piperazines have been associated with multiple 
fatalities and was one of the top 25 identified drugs in 2011. (1, 2). While circumventing 
legislative controls and preventing the detection in standard drug tests, synthetic piperazine 
derivatives are encountered in forensic casework as “legal” alternatives to ecstasy (3,4-
methylenedioxymethamphetamine) (3). These chemically-produced compounds share 
very similar pharmacological and psychological effects with ecstasy which in turn has led 
to their popularity as “party pills” (3). The long-lasting duration of synthetic piperazines, 
especially when 1-benzylpiperazine (BZP) is mixed with 1-(3-trifluoromethylphenyl)-
piperazine (TFMPP), has also made them desirable to drug users to receive enhanced 
hallucinogenic effects (4).  
 Although most methods are optimized to accurately quantify the amount of drugs 
in biological specimens submitted for forensic toxicology testing, unforeseeable challenges 
may arise to complicate the analysis such as postmortem redistribution, enzymatic 
reactions, the presence of bacterial activities, chemical and matrix interferences as well as 
the lack of reference materials (5-7). Thus, the purpose of this research was to investigate 
the stability of synthetic piperazines in human whole blood under various storage 
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conditions and time ranges. A total of eight synthetic piperazines were assessed on their 
degrees of degradation using a Shimadzu Ultra-Fast Liquid Chromatography (UFLC) with 
SCIEX 4000 Q-Trap Electrospray Ionization Tandem Mass Spectrometry in positive 
ionization mode. These analytes included: 1-benzylpiperazine (BZP), 1-(4-fluorobenzyl)-
piperazine (FBZP), 1-(4-methylbenzyl)-piperazine (MBZP), 1-(4-methoxyphenyl)-
piperazine (MeOPP), 1-(para-fluorophenyl)-piperazine (pFPP), 1-(3-chlorophenyl)-
piperazine (mCPP), 2,3-dichlorophenylpiperazine (DCPP), and 1-(3-
trifluoromethylphenyl)-piperazine (TFMPP). 
 Individual unknown samples were prepared by spiking certified reference standards 
(Cayman Chemical, Ann Arbor, MI, U.S.A.) of each synthetic piperazine into certified 
drug-free human whole blood (UTAK Laboratories, Inc., Valencia, CA, U.S.A.) 
independently at 1000 ng/mL. To closely monitor the stability of each compound and 
potential drug-drug interactions, mixed samples consisted of all eight piperazines were also 
stored at room temperature (~20°C), 4°C and -20°C for one, three, six, nine and twelve 
months in dark sealed containers. Solid phase extraction (SPE) was performed to remove 
unwanted components prior to the injection into the LC system. Drug of Abuse (DAU) 
mixed-mode copolymeric columns (Clean Screen®, UCT Inc., Levittown, PA, U.S.A.)  
were utilized with a positive pressure manifold rack followed by evaporating to dryness 
with low heat at 65°C. All samples were then reconstituted with 250 µL of 50:50 mixture 
of methanol and 2mM ammonium formate buffer with 0.2% formic acid (Fisher Scientific, 
Waltham, MA, U.S.A.).  
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Analysis was performed in triplicate using a reversed-phase column (Kinetex® F5, 
Phenomenex®, Torrance, CA, U.S.A.) with a binary gradient of a 2mM ammonium 
formate buffer with 0.2% formic acid and methanol with 0.1% formic acid. The total run 
time was 11.5 minutes including equilibration and the flow rate was 0.4 mL/min. Three 
internal standards including BZP-d7, mCPP-d8 and TFMPP-d4 (Cerilliant, Round Rock, 
TX, U.S.A) were used to generate calibration curves that were ranged from 20 ng/mL to 
2000 ng/mL.  
Results revealed that BZP, MBZP and FBZP were more stable than phenyl 
piperazines over time under all storage conditions, in which MBZP was consistently more 
stable and still had more than 70% remaining after 12 months. Data showed a smaller 
degree of degradation when samples were kept frozen or refrigerated; whereas storing at 
room temperature should be avoided to ensure minimal degradation and detrimental 
impacts on stability of piperazine compounds. For crime laboratories that are facing 
backlog situations, case samples with synthetic piperazines should be kept frozen or 
refrigerated even for time period as short as 30 days or less. However, storing them for too 
long will clearly affect the quantitation accuracy because phenyl piperazines are more 
susceptible to degrade completely after six months regardless of storage conditions. 
Additionally, matrix interference was present due to the outlier of MBZP quantified on 
Day 270. Drug-drug interaction was also observed in the analyte mixture but the exact 
stability pattern of phenyl piperazines when mixed together could not be determined from 
this data set alone due to discrepancies observed on Day 91 and 270.  
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This research project had shown a solid method to examine how quickly or slowly 
synthetic piperazines degrade in blood at different storage conditions. To further this study, 
it would be also important to evaluate the number of freeze-thaw cycles on each specimen 
in order to minimize the effect of non-metabolic degradation.   
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1. INTRODUCTION 
1.1 New Psychoactive Substances 
1.1.1 History of Designer Drugs 
In the 1970s, “designer drugs” referred to multiple heroin-like synthetic substances 
derived mostly from the fentanyl molecule (8). Later in the mid-1980s, this term gained 
widespread popularity when 3,4-methylenedioxymethamphetamine (MDMA) underwent 
a popularity growth (8). Although the term “designer drugs” has been described informally 
as “legal highs” in the past ten years, the preferred term is “new psychoactive substances” 
(NPS) (9). NPS cover a large number of recreational drugs that mimic the effects of existing 
controlled substances and are often sold as “legal highs” to circumvent legal authorities 
(2).  For example, piperazines derivatives, which belong to a class of amphetamine-like-
compounds, are making a resurgence as “legal Ecstasy” (3). Studies showed that NPS may 
pose a threat to the public health comparable to scheduled substances, but these compounds 
can be distinguished from classical drugs of misuse such as amphetamine, cocaine, 
cannabis and heroin because of little or no history of medical use (9).  
 
1.1.2 Wide Spread Internet Availability 
 The rapid and continuous emergence of NPS that have not been scheduled poses 
serious safety issues. Due to the growing business of head shops and the internet in the late 
1990s and early 2000s, there was a huge explosion in designer drugs being sold in or over 
these sites because many synthetic or naturally derived psychoactives were legal to possess  
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(8). As a result, these derivatives appeared in a regular manner on the black market 
worldwide. Many of these substances are often sold, perceived as safe by the public and 
mislabeled as “research chemicals” which are not suitable for human consumption (2). 
During the time that the euphemism “research chemicals” appeared, the internet provided 
drug sellers new channels for their businesses and even for online “chat-rooms” where the 
efficacy of drugs could be discussed without censor (9). Selling designer drugs on the 
internet is still a growing problem that is dangerous to the public. 
 
1.2 Synthetic Piperazines 
1.2.1 Original Use 
 Piperazine-based compounds are completely synthetic rather than “herbal” as 
suggested by some suppliers. They can be divided into two classes, the benzylpiperazines 
such as 1-benzylpiperazine (BZP) and the phenylpiperazines such as 1-(3-
trifluoromethylphenyl)-piperazine (TFMPP) (10). Piperazines are primarily used as 
anthelmintic agents in veterinary and clinical practices (1). Although BZP was originally 
synthesized by researchers in 1944 from a pepper plant to serve as a potential de-worming 
agent for farm animals in particularly cattle, scientific data was not published in regards to 
the use of BZP as a treatment for intestinal parasites in human (10). According to the 
literature in the 1970s, several studies were conducted on BZP being a potential 
antidepressant medication but was rejected due to its amphetamine-like effects with high 
potential for abuse (4). Moreover, the piperazine ring and its derivatives are often seen in 
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the industrial field and used as important raw materials for the hardrning of epoxy resins, 
corrosion inhibitors, rubber accelerators, urethane catalysts and antioxidants (4).  
 
1.2.2 Arise in Synthetic Piperazines Abuse  
The first documented abuse of a piperazine derived drug with BZP was reported in 
the United States of America (U.S.A.) in 1996 (10). In 2000, piperazine-related abuse has 
begun to spread in New Zealand and Australia (11). In September of 2004, 1-(3-
chlorophenyl)-piperazine (mCPP), which was “marketed” as the new ecstasy-like 
substance during that time, was detected in street drugs in Sweden as well as the 
Netherlands by the Drug Information and Monitoring System (10). According to the U.S. 
National Forensic Laboratory Information System (NFLIS), about 38,230 piperazines were 
seized from 2006 to 2010 and this class of drugs was one of the top 25 identified drugs in 
2011 (1). The accessibility of obtaining piperazine derivatives at a party-type environment 
and their recovery rates during synthesis stand out among other recreational drugs. This is 
largely because piperazines can be adulterated with many external binders such as caffeine 
and vitamins that are usually inexpensive (4). Another reason that piperazines have been 
promoted to the youth population is their long-lasting duration, which is typically four to 
six hours. If BZP is mixed with TFMPP in order to enhance its spectrum effects, this 
specific combination can last up to eight hours (4). According to the United Nations Office 
on Drugs and Crime (UNODC), there were at least twelve substituted synthetic piperazines 
drugs on the clandestine drug market as of 2013 (12) in which only few are currently 
regulated.  
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Not only are synthetic piperazines used recreationally, but they are also more 
prevalent in the military (1). In 2008, the Forensic Toxicology Drug Testing Laboratory 
(FTDTL) within the military system located in Florida had seven unconfirmed urine 
specimens that were preliminarily detected as amphetamine positive, in which all 
specimens were subsequently quantitatively confirmed by gas chromatography-mass 
spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) of 
containing different levels of BZP, TFMPP and mCPP (1). Thus, the result had raised 
concerns over abuse of piperazines in the military.  
 
1.2.3 Mechanism and Effect  
Since an addition or removal of merely one functional group on each chemical 
structure may entirely alter the effect of each drug (13), it is important for analysts to 
understand the mechanism behind each class of drugs. Previous animal studies have 
emphasized that some synthetic piperazines can both stimulate the release and inhibit the 
reuptake of dopamine, serotonin (5-HT) and noradrenaline, in which serotonergic and 
dopaminergic effects predominate in most cases (11). Nonetheless, the majority of NPS 
have not been extensively studied as they are relatively new to the scientific community. 
As a result, many of the pharmacological properties remain unclear, such as absorption 
rate, distribution, metabolism, excretion, major psychological effects and even potency of 
the drug molecule (14). As of today, TFMPP, BZP and mCPP are the only synthetic 
piperazines that have been studied in detail in terms of their pharmacodynamic and 
pharmacokinetic properties. 
5 
 
Among the eight synthetic piperazines that were studied in this project including 1-
benzylpiperazine (BZP), 1-(4-fluorobenzyl)-piperazine (FBZP), 4-methyl-1-
benzylpiperazine (MBZP), 1-(4-methoxyphenyl)-piperazine (MeOPP), 1-(para-
fluorophenyl)-piperazine (pFPP), 1-(3-chlorophenyl)-piperazine (mCPP), 2,3-
dichlorophenylpiperazine (DCPP), and 1-(3-trifluoromethylphenyl)-piperazine (TFMPP), 
the pharmacological effect of BZP is proven to be similar to MDMA and shares highly 
similar dopamine and serotonin agonist mechanism of action (4). Although people who 
consumed BZP were reported to experience stimulant effects such as elevated blood 
pressure and increased heart rate, increased euphoria, dysphoria, sociability and drug-
liking, it was found to be about 10-fold less potent than MDMA, methamphetamine or 
amphetamine  (11). No death record has been reported following a sole ingestion of BZP, 
but some of the severe toxic effects include psychosis, renal toxicity and seizure (4).  
 mCPP, a metabolite of commonly prescribed anti-depressants such as trazodone, 
nefazodone, enziprazole and etoperidone, has also been found to interact with specific 
serotonin receptors and thus lead to serotonin release (11, 15). A number of human clinical 
studies have indicated that the major metabolite of mCPP is believed to be para-hydroxy-
mCPP (p-OH-mCPP) via CYP2D6-mediated hydroxylation (11). In order not to overlook 
further toxic compounds in poisoning cases, confirming the presence of other metabolites 
is therefore relevant for toxicological risk assessment and for drug screening purposes in 
forensic toxicology laboratories. Negative effects of mCPP are very similar to those as a 
result of serotonin syndrome (15). Some of these effects include anxiety, dizziness, 
confusion, depressive symptoms, panic attacks as well as sensitivity to light and noise (4).  
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TFMPP acts as a non-selective serotonin receptor agonist in addition to boosting 
synaptic serotonin levels by blocking serotonin reuptake and increasing its release (11) . 
Although information is lacking on this compound, TFMPP is rarely administered by itself 
but often mixed with BZP as a party pill instead (1). As a result, TFMPP has amphetamine-
like effects as well.  
Besides BZP, TFMPP and mCPP, the following piperazines have been synthesized 
and introduced into the illicit market and may pose dangerous threat to the public health 
system: they are MeOPP, pFPP and MBZP. The average duration of MeOPP is shorter than 
that of BZP and does not have strong stimulant effects, whereas pFPP is a piperazine 
derivative with mild hallucinogenic and euphoric effects (4, 9). Both MeOPP and pFPP 
have been found in vitro to play an important role as a serotonin receptor agonist (4). 
Moreover, MBZP is a stimulant drug which is a derivative of BZP. Despite its stimulant 
effect is comparatively weaker and it seems to create less problems such as nausea and 
headaches, the overall effect of MBZP is more or less the same to those of BZP (4).  
 
1.2.4 Legislative Control and Statistics 
 From the effective “internet marketing” of designer drugs to the huge demand in 
recreational use, the rapid growth of synthetic piperazines significantly outpace the ability 
of government to regulate, legislate and to enforce new policies. The UNODC and 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) had categorized 
piperazines into their standardization list to emphasize the risk of consuming this particular 
class of drugs (16).  
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In the United States, some synthetic piperazine compounds are placed under the 
Controlled Substances Act (CSA), which was amended by the Controlled Substance 
Analogue Enforcement of 1986 in order to prohibit the illegal manufacturing, selling or 
possessing of drugs (8). Although the majority of synthetic piperazines seized from 2006 
to 2010 were identified as BZP or TFMPP which had 4,180 and 1,084 cases respectively, 
only BZP has been permanently placed under the CSA and listed as a Schedule I substance 
(17, 18). The scheduling was determined after several thorough reviews of the drug’s abuse 
pattern, distribution and other relevant scientific data (19). The Drug Enforcement 
Administration (DEA) ruled that BZP has no legitimate medical use in the United States. 
Also, it does not seem to be safe to use under medical supervision and has a high potential 
for abuse which could result in a physical dependence (19). On the other hand, although 
the DEA temporarily listed TFMPP in 2002 as a Schedule I hallucinogen (17), the Food 
and Drug Administration (FDA) did not recommend placing regulations on this particular 
synthetic piperazine and had removed TFMPP from the CSA after March 2014 based on 
scientific data and multiple medical evaluations (20). Despite TFMPP’s lack of placement 
on the CSA at the federal level, it is still a scheduled drug in Florida according to its State 
statute (21).  
Reports and statistic data reveal that the presence of illicit drugs in whole blood 
samples originating from motor vehicle drivers might be a contributing factor in causing 
traffic accidents and in initiating violent behaviors (22). Therefore, it is imperative to have 
regulations governing the use of these psychoactive substances in order to help lower the 
rate of criminal cases as well as fatal vehicle accidents.  
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1.3 Detection of New Psychoactive Substances 
1.3.1 Traditional Methods 
            The successful detection of illicit drug consumption or nonmedical intake of 
prescription medications is essential in different arenas including criminal investigations, 
cases involving driving under the influence, performance enhancement tests as well as 
military drug testing. In spite of the increasing number of designer drugs available, only 
few comprehensive screening techniques are currently available for NPS detection and 
quantification in biological specimens (23). While GC-MS and LC-MS are traditionally 
the analytical method of choice, many of the ever-changing designer drugs entities do not 
exist within the mass spectral library (22, 23). Although the mass spectrometric theory of 
the three-dimensional quadrupole ion trap can be traced back to about thirty years ago when 
the first commercially available instrument got released to the market (24), limitations still 
exist on these instruments in terms of sensitivity and specificity . For example, the GC-MS 
method is still limited only to non-polar, volatile and thermally stable compounds that 
generally requires time-consuming sample preparation and derivatization (22).  
 In the case of seized drugs, multiple preliminary tests for the presumptive 
identification of NPS are currently available but false positives with these tests have been 
known to occur especially if the amphetamine class of compounds are involved in the 
testing method (10). Although synthetic piperazines have been tested with various color 
tests and immunoassays, no color test has been accepted in the forensic community and no 
immunoassay kit has been found to be specific to piperazines (14).  
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1.3.2 Potential Alternatives 
In order to analyze a large number of routine case samples within a given time in 
the field of forensic science, a user-friendly software coupled with an economically-
efficient hardware are highly desirable. For instance, high performance liquid 
chromatography (HPLC) and ultra-fast liquid chromatography (UFLC) are both considered 
as a robust alternative with minimal sample preparation and high sample throughput (22).  
Moreover, high-resolution mass spectrometry (HR-MS) has been used as a 
screening tool involving untargeted and general unknowns within the field of forensic 
toxicology (24). Nevertheless, the cost of HR-MS instrumentation such as a quadrupole-
time-of-flight is often a drawback that prohibits its use in toxicology laboratories even 
though it is an ideal tool to identify designer drugs by exact mass analysis (23). In summary, 
LC-MS has gained popularity in the field of forensic toxicology because of its ability to 
perform reliable qualitative and quantitative analysis. 
 
1.4 Multiple Challenges  
1.4.1 Chemical Interference 
 At most medical examiner offices, autopsy samples are usually collected for drug 
analysis on suspicious cases prior to an embalming process (25). Occasionally, the 
embalmed tissue will be later analyzed if there is a false negative result from an initial drug 
screen or no initial suspicion of drug involvement in the death (26). The latter scenario 
becomes a problem because the presence of formalin and formaldehyde in biological 
samples which might contribute different degrees of interaction with the drug present in 
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the decedents’ body (26). Since both formalin and formaldehyde are two highly reactive 
preservative fluid that are commonly used in the embalming process, previous studies have 
shown that formaldehyde-embalming solution can be reactive with various controlled 
substances such as barbiturates, diazepam, phenytoin, fenfluramine and tricycli 
antidepressants (27). With that being said, drug stability is one of the major concerns when 
body undergoes numerous postmortem changes in forensic casework regardless of if the 
sample is obtained either ante- or post-mortem.  
 
1.4.2 Limited Toxicological References / Structural Similarity  
 A lot of NPS are considered as emerging drugs which are not easy to detect in 
traditional toxicological analysis (28). Most data are obtained mainly from reported 
intoxication cases or drug users forums. As a result, limited data is available about the 
pharmacological effects and metabolism of these designer drugs, such as BZP and TFMPP 
(29). Additionally, due to a high structural similarity of piperazine-based drugs, current 
analytical methods are often not sensitive or specific enough to distinguish closely-related 
analytes while cross-reaction with other amphetamines have indeed been reported (28, 29). 
Therefore, the metabolism pathway and psychological effects of synthetic piperazines 
remain unclear for the most parts while their popularity as recreational drugs have grown 
(29).  
 In some substance abuse cases, drugs can be difficult to identify from a forensic 
analytical point of view due to the large number of potential structures. However, the 
constant introduction of novel compounds, the lack of literature references, inadequate 
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accessibility to standards and the lack of comprehensive analytical methods which all 
negatively contribute to the issue (23).   
 
1.4.3 Logistic Nature & Storage Conditions 
 Knowledge of the pharmacological information of a drug is of importance for 
forensic toxicologists, but backlog situations in laboratories cannot be overlooked. The 
limitations of a logistic nature often prevent analysts from obtaining reliable quantitative 
data due to variable time intervals between obtaining a sample and analysis (5).  
 Furthermore, storage conditions of specific drugs or compounds in biological 
samples may affect the analytical results due to ongoing enzymatic metabolism and post-
mortem redistribution (5, 7). In terms of drugs instability, chemical degradation or even 
bacterial activities may potentially become an issue that presents challenging 
interpretations on analytical results (5, 6). For example in 2013, a study on the investigation 
of stability of mephedrone in blood demonstrated significant degradation after storing it 
for just seven days at 4̊ C (7).  
 
1.5 Research Objectives / Hypothesis 
 Synthetic piperazines, like other emerging designer drugs currently available on the 
market, have been constantly growing in terms of rate of drug abuse and death rate related 
to drug overdose. If federal agencies or local legislatures regulate and list them as 
controlled substances, a well-developed method is necessary to detect and accurately 
quantify synthetic piperazines in biological matrices such as blood and urine. However, the 
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forensic community is short of confirmatory and quantitative methods on piperazines and 
they tend to be limited to the analysis of BZP and TFMPP (29). More importantly, stability 
of synthetic piperaines in whole blood samples remains unknown due to the fast-changing 
structure of novel drugs as well as the lack of references. Therefore, in partial to validate a 
reliable method according to the Scientific Working Group for Forensic Toxicologists 
(SWGTOX) guidelines for quantitative methods, an investigation on stability of synthetic 
piperazines is required in order to examine possible degradation of seized drugs in 
biological samples. This will not only be impactful in terms of quantitative data analysis 
on routine case samples, but also in maintaining public health and safety. 
 The ultimate goal of this research was to examine the degree of degradation and the 
amount loss of each tested synthetic piperazine in blood over time. Since storage condition 
is one of the key components of analyte stability, all synthetic piperazines including BZP, 
MBZP, FBZP, MeOPP, pFPP, mCPP, DCPP, and TFMPP were stored separately at room 
temperature (~20̊ C), 4̊ C and -20̊ C for different periods of time. Quantitation on each 
analyte was performed with the use of three deuterated internal standards of BZP-d7, 
mCPP-d8 and TFMPP-d4. Drug-drug interaction and analyte interference were also 
investigated by storing samples with all piperazines mixed together. Quantitative analysis 
was performed using an Ultra-Fast Liquid Chromatography – Electrospray Ionization- 
Tandem Mass Spectrometry (UFLC-ESI-MS/MS) in order to obtain accurate and precise 
readings. The results were assessed in full accordance with the SWGTOX guidelines 
including evaluation of accepted range of accuracy and coefficient of determination which 
is also known as the R2 value.  
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Figure 1: Chemical structures. (A) Synthetic piperazines BZP, FBZP, MBZP, TFMPP, 
mCPP, MeOPP, DCPP and pFPP (30). (B) Chemical structures of internal standards BZP-
d7, mCPP-d8, and TFMPP-d4 (30). 
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2. MATERIALS AND METHODS 
2.1 Theory of Instrumentation 
2.1.1 Liquid Chromatography 
 To optimize the effectiveness of each analytical run, the analyte of interest must be 
separated from other components in the sample matrix. Liquid chromatography (LC) is 
widely used as a separation technique based on an adsorption mechanism where molecules 
and ions adhere to the surface of the absorbent, which is commonly known as the stationary 
phase (31). In general, stationary and mobile phases are two media in which sample 
distributes based on levels of affinity or polarity. Samples are dissolved in mobile phase 
and forced through the column that houses the stationary phase. Molecules with a weak 
affinity for the stationary phase move rather quickly so that sample components are 
separated into discrete bands for analysis based on different migration rates. For example, 
a nonpolar molecule tends to stick to a nonpolar stationary phase via weak intermolecular 
forces. However, this nonpolar molecule will only have little affinity for a polar stationary 
phase.  
 In addition to stationary phase, it is also important to manipulate and optimize each 
set of parameter independently in order to identify and quantitate complex mixtures. For 
instance, column dimensions, chemical compositions of column, initial and final mobile 
phase compositions as well as gradient time are all influential in terms of method 
optimization (32). Some examples of mobile phases used in a LC system include 
acetonitrile, methanol, water, formic acid and buffer. A typical analytical column is coated 
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with silica and may have modified surface depending on the chemistry or interaction 
between the analyte of interest and the coating material.  
In addition to regular LC, high-performance liquid chromatography (HPLC) and 
ultra-high-performance liquid chromatography (UHPLC) are both powerful techniques for 
identification and quantification. Although HPLC is more cost-effective, UHPLC offers 
enhanced separation power and reduced run times that make it more desirable in the 
forensic context (31).    
 
2.1.2 Mass Spectrometry   
 Mass Spectrometry (MS) is an analytical technique in which sample molecules are 
ionized in the gas phase and fragmented into different patterns that can be used to obtain 
structural information (33). It is often used as a definitive detector to ionize, separate and 
identify generated ions of a wide variety of evidence including controlled substances and 
fire debris. A typical MS consists of five major components: a vacuum system, an ion 
source, a mass analyzer, an ion detector and a data recording system. Normally, MS is 
coupled with either a gas chromatography (GC) or a LC system to accelerate the separate 
process.  
 The vacuum system in MS can prevent unwanted collisions between generated gas-
phase ions and neutral molecules. In addition, operating under vacuum can increase the 
mean free path of fragment ions. Once all sample molecules are ionized by the ion source, 
the produced ions can then be transported to the mass analyzer where they can be separated 
based on individual mass-to-charge (m/z) ratio. Subsequently, the intensity of each m/z is 
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recorded so ion signal can be amplified and digitized in the data recording system. Data is 
then formulated as a spectrum, or a plot of intensity versus m/z (31). 
 In spite that multiple ion sources exist, electron ionization is a type of ion source 
where high-energy electrons emitted from a resistively heated filament travel in spiral 
pathways toward the anode in order to increase the probability of bombarding sample 
molecules (31). In other words, a high-energy collision occurs which breaks down 
molecules into smaller pieces of fragment ions, which is also known as fragmentation (31). 
After the molecule is ionized, fragment ions are charged so they can be accelerated through 
the mass analyzer (34).  
 
2.1.3 Electrospray Ionization   
While atmospheric pressure chemical ionization and electron ionization are two 
popular choices to volatize and ionize compounds for mass spectrometric analysis, 
electrospray ionization (ESI) has been gaining recognition and acceptance within the 
forensic community (31, 33). Unlike chemical ionization, ESI is a soft ionization technique 
in which pseudo molecular ions can be easily observed due to milder fragmentation (31). 
The electrospray source is comprised of a capillary tube and a counter electrode that creates 
electric field. As the sample molecules moving along the capillary tube, there is an 
accumulation of charge on the surface of the liquid. A pure, hot nebulizing gas, such as 
nitrogen, is then applied for turning the liquid sample into fine mist. As the solvent 
evaporates, the droplet size decreases whereas the electrical charge density increases on its 
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surface (31). Eventually, smaller droplets will be formed due to repulsion between like 
charges that can overcome the surface tension (31).  
 
2.1.4 Tandem Mass Spectrometry 
 A tandem mass spectrometer (MS/MS) is two mass spectrometers linked together 
and consists of two single quadrupole instruments. In theory, tandem mass spectrometers 
have three quadrupole in series: the first and third quadrupole are mass analyzers whereas 
the second quadrupoles serves as a collision cell (31). The first quadrupole (Q1) acts as a 
mass filter that will mainly transmit a selected ion, or precursor ions, towards the collision 
cell (Q2). In Q2, ion molecules interact and collide with neutral gas under high pressure. 
The fragment ions are then moved into the third quadrupole (Q3) for another round of 
scanning mass filtering before entering the detector (35). Thus, tandem mass spectrometry 
is also known as triple quadrupole mass spectrometry despite the collision cell is not a mass 
analyzer and does not function as a separator.   
 The quadrupole mass analyzer is a four-parallel-conducting-rod compartment in 
square shape. Direct current and radio frequency are applied on assigned rods so only ions 
of a specific m/z can resonate with the current at a time (31, 35). Although quadrupoles 
yield a lower resolution, they are comparatively inexpensive and user-friendly (35).  
2.2 Materials  
2.2.1 Standards / Reagents 
 The following reagents were purchased from Fisher Scientific (Waltham, MA, 
U.S.A): LC grade methanol, LC grade 2-propanol (same as isopropanol), optima grade 
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acetonitrile, optima grade formic acid, methylene chloride, ammonium formate, 
concentrated ammonium hydroxide, concentrated hydrochloric acid, anhydrous disodium 
phosphate and monohydrate sodium dihydrogen phosphate. BZP, FBZP, MBZP, MeOPP, 
pFPP, mCPP, TFMPP and DCPP were purchased through Cayman Chemical Company 
(Ann Arbor, MI, U.S.A.) All piperazines were received in the form of 10 mg powder except 
for BZP, which was received as a 1 mg/mL standard in methanol. Three deuterated internal 
standards, BZP-d7, mCPP-d8 and TFMPP-d4, were received as 100 µg/mL standards in 
methanol from Cerilliant Corporation (Round Rock, TX, U.S.A.). Fresh millipore water 
was obtained daily from the Synergy UV water filtration system from EMD 
Millipore/Merck (Darmstadt, Germany). Certified drug-free human whole blood was 
purchased from UTAK Laboratories, Inc. (Valencia, CA). During mobile phases and 
reagents preparation, an Oakton pH meter from Fisher Scientific was used to confirm the 
pH level. During sample preparation, solid phase extraction (SPE) was conducted on a 
positive pressure manifold made by UCT, Inc. (Bristol, PA, U.S.A). Additionally, Clean-
Screen Drug of Abuse (DAU) 200 mg/ 6 mL solid phase extraction cartridges were also 
purchased from UCT, Inc. 
Table 1: Lot numbers of certified reference materials. All certified reference standards 
were stored at -20̊C 
 
Product Company  Lot Numbers 
BZP Cayman Chemical 0470646-1 
BZP-d7 Cerilliant FE06221504 
FBZP Cayman Chemical 0435859-14, 0435859-19 
MBZP Cayman Chemical 0465260-5, 0465260-6 
MeOPP Cayman Chemical 0446981-12, 0446981-13 
pFPP Cayman Chemical 0435857-30 
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mCPP Cayman Chemical 0446996-11, 0446996-18  
mCPP-d8 Cerilliant FN071111-01 
TFMPP Cayman Chemical 0435854-36 
TFMPP-d4 Cerilliant FN08011407 
DCPP Cayman Chemical 0446497-12, 0446497-15 
Whole Blood  UTAK B1027, B1086 
 
2.2.2 UFLC-ESI-MS/MS  
   Quantification of synthetic piperazines was performed using a Shimadzu 
Prominence Ultra-Fast Liquid Chromatography System with two LC-20AD model pumps 
and a SIL-20AC model auto-sampler (Kyoto, Japan). The separation was achieved using a 
Kinetex® F5 2.6µm, 100 Å, 150 mm x 3.0 mm ID column from Phenomenex, Inc. 
(Torrance, CA, U.S.A). All analytes were detected on a SCIEX 4000 QTRAP tandem mass 
spectrometer consisting of a Turbo V electrospray ionization source (Framingham, MA, 
U.S.A). All data were collected using Analyst™ (version 1.6.2) software and quantitation 
was conducted with MultiQuant™ 3.0 (version 3.05373.0) software (SCIEX).  
 
2.3 Methods 
2.3.1 LC-MS/MS Method Parameters 
 The method utilized in this project was adapted from the compound and source 
optimization processes conducted by Leblanc, whose thesis focused on method 
development and validation for the quantification of different synthetic piperazines in 
blood and urine (30). After evaluating each analyte and internal standard, the two most 
intense product ions and the single most intense ion were selected respectively. Analytes 
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that were labelled “1” were the most intense fragment ions that were used for quantitation 
purposes of that particular analyte; whereas the second most intense fragment ion was 
labelled “2” as a confirmatory ion of that specific analyte. Table 2 shows the dwell time, 
declustering potential (DP), collision energy (CE), cell exit potential (CXP) and entrance 
potential (EP) that were optimized for each analyte and internal standard. The duration of 
the MRM scan was set to 6.5 minutes and all analyses were conducted in positive ionization 
mode. In addition, Table 3 shows the optimized gas and ion source parameters used in this 
experiment.   
Table 2:  Multiple Reaction Monitoring (MRM) Table  
 
Name of 
Analyte 
Q1 
Mass 
(Da) 
Q3 
Mass 
(Da) 
Dwell 
Time 
(msec) 
DP 
(V)  
EP 
(V) 
CE 
(V) 
CXP 
(V) 
BZP-d7 IS 1 184.3 98.2 50 70.0 10 30.0 15.0 
BZP 1 177.1 91.1 50 66.0 10 32.0 14.0 
BZP 2 177.1 65.1 50 66.0 10 63.0 9.0 
FBZP 1 195.2 109.1 50 72.0 10 29.0 18.0 
FBZP 2 195.2 83.2 50 72.0 10 65.0 12.0 
MBZP 1 191.2 91.1 50 75.0 10 31.0 15.0 
MBZP 2 191.2 65.2 50 75.0 10 67.0 9.0 
MeOPP 1 193.2 150.2 50 70.0 10 28.0 24.0 
MeOPP 2 193.2 119.3 50 70.0 10 34.0 19.0 
pFPP 1 181.2 138.2 50 75.0 10 29.0 23.0 
pFPP 2 181.2 75.2 50 75.0 10 77.0 11.0 
mCPP 1 197.1 154.2 50 75.0 10 28.0 26.0 
mCPP 2 197.1 118.2 50 75.0 10 48.0 19.0 
mCPP-d8 IS 1 205.4 158.2 50 86.0 10 31.0 26.0 
DCPP 1 233.1 190.2 50 85.0 10 30.0 32.0 
DCPP 2 233.1 117.2 50 85.0 10 67.0 19.0 
TFMPP 1 231.1 188.1 50 80.0 10 32.0 33.0 
TFMPP 2 231.1 118.3 50 80.0 10 54.0 19.0 
TFMPP-d4 IS 1 235.4 190.2 50 84.0 10 32.0 32.0 
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Table 3:  Ion source and gas parameters.  
 
Curtain 
Gas (psi) 
Collision 
Gas 
IonSpray 
Voltage (V) 
Temperature 
(̊C) 
Ion Source 
Gas 1 (psi) 
Ion Source 
Gas 2 (psi) 
30 Medium 2500 600 50 80 
 
The two mobile phases used in this method were 2mM ammonium formate buffer 
with 0.2% formic acid (mobile phase A) and HPLC-grade methanol with 0.1% formic acid 
(mobile phase B). In terms of LC settings, the flow rate was set to 0.400 mL/min in which 
the starting condition was 5% mobile phase B. The injection volume was set to 5 µL. The 
maximum pressure for both LC pumps was set to 5000 psi and a binary flow was selected 
as the pumping mode. In order to prevent contamination, parameters of the auto sampler 
were optimized as listed in Table 4.  
Table 4: Auto sampler settings  
Rinsing 
Volume 
Needle 
Stroke  
Rinsing 
Speed  
Sampling 
Speed 
Purge 
Time 
Rinse Dip 
Time 
Cooler 
Temperature  
1000 µL 52 mm 35 µL/sec 2.0 µL/sec 25 min 0 sec 15°C 
 
 This method has a 1.50 minutes of pre-equilibration to ensure the starting 
conditions such as oven temperature and pressure of the LC system are met. As shown in 
Table 5, each analysis is designed to run with a gradient flow where the percentage of 
mobile phase B changes over time. Upon completion of the run, re-equilibration takes place 
from 6.51 to 10.00 minutes. 
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Table 5:  LC time program.  
Time (min) Module Event Parameter (%) 
0.01 Pumps Pump B Concentration 5 
0.30 Pumps Pump B Concentration 5 
3.50 Pumps Pump B Concentration 80 
6.50 Pumps Pump B Concentration 80 
6.51 Pumps Pump B Concentration 5 
10.00 Controller Stop  
 
2.3.2 Preparation of Calibrators and Stored Samples 
 Besides BZP which was prepared with methanol by the manufacturer, all piperazine 
standards purchased from Cayman Chemical were individually prepared at 1 mg/mL by 
weighting 1 mg of powder and dissolving it in 1 mL of LC grade methanol followed by 
vortexing it for 30 seconds. Each solution was then serially diluted to make a 10 µg/mL 
stock from the 1 mg/mL solution. To further prepare a 1 µg/mL stock solution (Stock 1), 
the above 10 µg/mL stock solution from each analyte were combined and diluted with 
50:50 of millipore water and methanol. Stock 1 solution was further diluted to make a 100 
ng/mL stock solution (Stock 2) with the same solvent. An internal standard stock solution 
(Stock 3) was prepared at a concentration of 1 µg/mL by combining BZP-d7, mCPP-d8 
and TFMPP-d4 obtained from Cerilliant. Calibrators ranged from 20 ng/mL to 2000 ng/mL 
were prepared in 15 mL glass tubes that contained different volume of stock 1 or stock 2 
along with 100 µL of certified drug-free whole blood. As shown in Table 6, every sample, 
except for double blanks, were spiked accordingly and fortified with 30 µL of stock 3. 
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Additionally, a high quality control (QC) sample and a low QC sample were prepared at 
1500 ng/mL and 30 ng/mL respectively. 
 Due to an interference of a stable isotope that has the same m/z in both DCPP and 
TFMPP, a separate calibration curve was required to accurately quantify the analyte of 
interest in order to avoid any possible underestimation of TFMPP. To prepare this special 
calibration curve, stock 1 and stock 2 solutions were prepared with TFMPP only where all 
other parameters as shown in Table 6 remained the same. 
For unknown samples preparation, eight different tubes of 10 mL certified drug-
free whole blood containing each synthetic piperazine were prepared independently at a 
concentration of 1000 ng/mL from the previously diluted 10µg/mL stock. In addition to 
the eight synthetic piperazines samples, a tube of 10 mL whole blood containing all 
synthetic piperazines standards as well as another tube of 10 mL whole blood served as 
control were also prepared. Subsequently, mixture analyte(s) or whole blood from those 
test tubes were transferred into two separate amber glass vials in which each vial contained 
3.3mL. They were then capped and placed at room temperature and 4 ̊ C for 1, 3, 6, 9 and 
12 month(s). The remaining 3.4 mL of mixture solution in the tube was also stored and 
wrapped in opaque tape to prevent degradation by light, and placed in the freezer at -20 ̊ C 
for 1, 3, 6, 9, 12 month(s). Temperatures for the freezer, refrigerator and the room where 
samples were stored were monitored and recorded every day except for the weekends. No 
internal standards were added into any samples on Day 0.  
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Table 6: Preparation of calibrators for generation of calibration curve. The table 
shows the amount of stock solution required to generate a calibration curve prior to solid 
phase extraction.  Stock 1 was a 1 µg/mL solution and Stock 2 was a 100 ng/mL solution. 
Both stocks contained all synthetic piperazines. The internal standard solution (Stock 3) 
was prepared at 1 µg/mL and contained all three deuterated internal standards. 
 
Calibrator/  
Sample 
Stock Solution 
(µL) 
Whole Blood  
(µL) 
Internal Standard 
Solution (µL) 
  Stock 1  Stock 3 
2000 ng/mL  200 100 30 
High QC (1500 ng/mL) 150 100 30 
1000 ng/mL  100 100 30 
500 ng/mL  50 100 30 
200 ng/mL 20 100 30 
 Stock 2   
100 ng/mL 100 100 30 
50 ng/mL  50 100 30 
Low QC (30 ng/mL) 30 100 30 
20 ng/mL  20 100 30 
Negative Control  N/A 100 30 
Double Blank  N/A 100 N/A 
 
 
2.3.3 Solid Phase Extraction  
 Solid phase extraction (SPE) was performed on all samples to purify and remove 
unwanted components from whole blood prior to the injection into the LC system. 1 mL 
of phosphate buffer (100 mM, pH 6) was added to all samples and was vortexed for 10 
seconds. Clean Screen Drug of Abuse (DAU) columns were loaded onto a positive pressure 
manifold rack and were conditioned with 1 mL of methanol followed by another 1 mL of 
phosphate buffer (100 mM, pH 6). No external artificial pressure was applied and only 
gravity flow was allowed during cartridges conditioning. Subsequently, samples were 
poured into each designated pre-conditioned column and were allowed to drip with gravity 
flow only. A series of wash steps were performed on each column in the order of 1 mL of 
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millipore water, 1 mL of 0.1 N hydrochloric acid and 1 mL of LC grade methanol. To dry 
sorbent on SPE columns, a full flow of compressed nitrogen gas was applied for 5 minutes 
at 40 psi.  
Samples were then transferred onto an elution rack followed by adding 2 mL of 
base elution solvent in which piperazines on the sorbent bed were eluted from the columns 
into new 15 mL glass test tubes. The base elution solvent was made fresh for each 
experiment. To avoid misty mixture solution, the base elution solvent was prepared in the 
order of adding 20% isopropanol (2-propanol), 3% of concentrated ammonium hydroxide 
and 77% of methylene chloride. Once all samples were eluted via gravity flow, test tubes 
were placed on a heating block at 65̊ C until the solvent was completely evaporated.  
After drying down all samples, they were reconstituted with 250 µL of 50:50 
mixture of methanol and 2mM ammonium formate buffer with 0.2% formic acid. All 
samples were transferred from the test tube to an LC-MS vial with a flat bottom liner and 
stored at the auto sampler chamber at 15 ̊ C. Using the LC-MS/MS method described 
previously, all samples were then run under the pre-set conditions.  
2.3.4 Quantification of Analytes  
 The stability of synthetic piperazines was examined by monitoring the amount loss 
of analytes over time at each storage condition. Quantification of synthetic piperazines in 
all samples were performed using LC-MS/MS and were compared to the calibration curves 
generated on both Day 0 and the end of each trial. Each sample was run three times and 
the average was obtained to serve as the initial concentration on Day 0 or the remaining 
concentration at the end of each trial. Data analysis was performed with MultiQuant™ 
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software and the following weighting factors were applied to the calibration curve: “area” 
was selected as the regression parameter while “1/x” was the weighting type to the linear 
regression line. Among the three deuterated internal standards, BZP-d7 was used to 
quantify BZP, FBZP and MBZP; mCPP-d8 was used to quantify MeOPP, pFPP, mCPP, 
and DCPP; TFMPP-d4 was used to quantify TFMPP only. 
 
 
 
 
 
 
 
 
 
 
 
  
27 
 
3. RESULTS AND DISCUSSION 
3.1 Analysis of 1-Month Samples  
The total length of this method was 11.5 minutes but all synthetic piperazines were 
expected to elute within the first 6.5 minutes. All benzyl piperazines were separated first 
with a lower retention time in which BZP was eluted at about 3.82 min, FBZP was eluted 
at about 4.48 min and MBZP was eluted at about 4.69 min. All phenyl piperazines were 
also eluted out at a different retention time: MeOPP at 5.09 min, pFPP at 5.33 min, mCPP 
at 5.80 min, DCPP at 6.11 min and TFMPP at 6.14 min. Although deuterated internal 
standards might co-elute with the target analytes at a similar retention time, they were all 
detected distinguishably at 3.71 min, 5.80 min and 6.15 min as BZP-d7, mCPP-d8 and 
TFMPP-d4 respectively.   
Since analyses were performed in triplicate, the quantitated data were recorded and 
the average of those three runs was calculated. The average value represented the 
concentration of each analyte stored alone or in mixed-mode on either Day 0 or Day 30. 
The standard deviation and the percent coefficient of variation (% CV) were calculated as 
shown in Table 7 by using the following formulas: 
Standard Deviation = √
∑ (𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑒𝑎𝑐ℎ 𝑟𝑒𝑝𝑙𝑖𝑐𝑎𝑡𝑒 − 𝑀𝑒𝑎𝑛)2
2
 
𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑉𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 (%𝐶𝑉) =
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑀𝑒𝑎𝑛
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Table 7: Average, standard deviation and percent coefficient of variation for analyte 
concentration in ng/mL on Day 0. All certified drug-free whole blood samples were 
fortified with the analytes at a concentration of 1000 ng/mL and run in triplicate. Analytes 
were prepared separately and in mixed-mode. The average concentration was calculated 
across these three runs. 
 
Analyte 
Average 
(ng/mL) 
Standard 
Deviation % CV 
 
Range (ng/mL) 
BZP 999.11 14.33 1.43 982.66 – 1008.87 
FBZP 1168.10 16.83 1.44 1156.63 – 1187.42 
MBZP 1140.45 20.65 1.81 1126.45 – 1164.16 
MeOPP 906.95 17.49 1.93 889.99 – 924.93 
pFPP 1142.07 18.77 1.64 1124.76 – 1162.02 
mCPP 980.95 0.90 0.09 1183.44 – 1224.04 
DCPP 795.72 18.31 2.30 778.21 – 814.74 
TFMPP 502.83 8.36 1.66 493.29 – 508.86 
MIX (BZP) 1195.24 1.70 0.14 1193.62 – 1197.01 
MIX (FBZP) 1148.76 21.62 1.88 1130.07 – 1172.44 
MIX (MBZP) 993.47 72.67 7.31 917.11 – 1061.78 
MIX (MeOPP) 1251.28 26.25 2.10 1223.26 – 1275.30 
MIX (pFPP) 1204.51 40.86 3.39 1177.36 – 1251.50 
MIX (mCPP) 1175.59 12.05 1.03 1161.72 – 1183.46 
MIX (DCPP) 882.04 17.04 1.93 866.54 – 900.28 
MIX (TFMPP) 461.74 2.92 0.63 458.48 – 464.12 
 
Table 8: Average, standard deviation and percent coefficient of variation for analyte 
concentration in ng/mL on Day 30 at different storage conditions. All samples were 
run in triplicate. The average concentration was calculated across these three runs. RT 
refers to room temperature.  
 
Analyte /  
Storage Condition 
Average 
(ng/mL) Standard Deviation % CV 
 
Range (ng/mL) 
BZP RT 1105.43 62.60 5.66 1054.4 – 1175.28 
BZP 4°C 949.15 53.16 5.60 887.76 – 980.12 
BZP -20°C 1166.81 51.16 4.38 1107.74 – 1196.79 
     
FBZP RT 787.14 10.27 1.30 776.82 – 797.36 
FBZP 4°C 902.95 124.78 13.82 795.24 – 1039.68 
FBZP -20°C 1295.06 38.63 2.98 1263.94 – 1338.29 
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MBZP RT 503.33 12.55 2.49 495.44 – 517.80 
MBZP 4°C 606.33 26.30 4.34 582.41 – 634.49 
MBZP -20°C 1144.13 60.45 5.28 1082.81 – 1203.68 
     
MeOPP RT 1238.79 50.78 4.10 1189.35 – 1290.82 
MeOPP 4°C 767.46 10.33 1.35 759.41 – 779.11 
MeOPP -20°C 961.05 3.48 0.36 957.78 – 964.72 
     
pFPP RT 1207.86 14.97 1.24 1192.02 – 1221.77 
pFPP 4°C 917.57 37.17 4.05 878.09 – 951.89 
pFPP -20°C 1073.07 34.24 3.19 1053.01 – 1112.60 
     
mCPP RT 1010.19 37.80 3.74 966.73 – 1035.41 
mCPP 4°C 973.45 13.62 1.40 964.31 – 989.11 
mCPP -20°C 978.83 10.23 1.04 971.99 – 990.58 
     
DCPP RT 1060.75 41.01 3.87 1018.16 – 1099.97 
DCPP 4°C 705.49 59.09 8.38 641.63 – 758.22 
DCPP -20°C 876.19 10.69 1.22 866.81 – 887.83 
     
TFMPP RT 499.42 22.57 4.52 481.18 – 524.66 
TFMPP 4°C 385.70 8.71 2.26 375.65 – 390.98 
TFMPP -20°C 686.05 54.35 7.92 641.83 – 746.74 
 
Table 9: Average, standard deviation and percent coefficient of variation for analyte 
concentration (in mixed-mode) in ng/mL on Day 30 at different storage conditions. 
All samples were run in triplicate. The average concentration was calculated across these 
three runs. RT refers to room temperature. 
 
Storage 
Condition Analyte 
Average 
(ng/mL) 
Standard 
Deviation % CV 
 
Range (ng/mL) 
MIX RT BZP 1173.39 87.50 7.46 1091.47 – 1265.56 
MIX 4°C BZP 1077.83 17.19 1.59 1066.53 – 1097.62 
MIX -20°C BZP 1027.91 53.34 5.19 989.22 – 1088.75 
      
MIX RT FBZP 1239.28 28.59 2.31 1206.85 – 1260.86 
MIX 4°C FBZP 1147.70 14.76 1.29 1132.77 – 1162.28 
MIX -20°C FBZP 1024.82 80.63 7.87 944.53 – 1105.79 
      
MIX RT MBZP 788.82 18.66 2.37 767.27 – 799.94 
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MIX 4°C MBZP 978.30 18.61 1.90 957.23 – 992.49 
MIX -20°C MBZP 1033.54 52.18 5.05 973.80 – 1070.16 
      
MIX RT MeOPP 554.17 12.72 2.29 539.51 – 562.24 
MIX 4°C MeOPP 528.09 7.93 1.50 522.66 – 537.20 
MIX -20°C MeOPP 263.30 9.53 3.62 254.35 – 273.32 
      
MIX RT pFPP 769.77 3.75 0.49 766.96 – 774.03 
MIX 4°C pFPP 728.55 17.42 2.39 709.31 – 743.28 
MIX -20°C pFPP 747.14 29.21 3.91 715.18 – 772.47 
      
MIX RT mCPP 639.97 26.23 4.10 620.56 – 669.81 
MIX 4°C mCPP 370.44 9.19 2.48 360.06 – 377.53 
MIX -20°C mCPP 409.71 23.30 5.69 386.05 – 432.63 
      
MIX RT DCPP 654.77 12.40 1.89 641.5 – 666.05 
MIX 4°C DCPP 322.97 8.04 2.49 315.66 – 331.58 
MIX -20°C DCPP 358.43 9.60 2.68 347.74 – 366.31 
      
MIX RT TFMPP 385.36 5.34 1.39 380.04 – 390.72 
MIX 4°C TFMPP 154.75 0.19 0.12 154.53 – 154.88 
MIX -20°C TFMPP 244.87 11.30 4.61 232.21 – 253.94 
 
 
 A fresh calibration curve was generated for each analysis on both Day 0 and Day 
30. The y-axis of the calibration curve indicated the ratio between the peak area of the 
analyte and peak area of internal standard, which is also known as the peak area ratio. The 
x-axis of the curve represented the concentration of analytes. As shown in Table 10, all 
coefficient of determination (R2 values) were above the minimum accepted value of 0.98.  
Table 10: R2 values of each analyte ran on calibration curve on Day 0 and Day 30. 
 
 BZP FBZP MBZP MeOPP pFPP mCPP DCPP TFMPP 
R2 value 
(Day 0) 0.9984 0.9978 0.9876 0.9950 0.9968 0.9990 0.9964 0.9978 
R2 value 
(Day 30) 0.9938 0.9998 0.9930 0.9936 0.9938 0.9998 0.9904 0.9974 
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 On Day 30, concentrations of synthetic piperazines that were kept in freezer showed 
little to no degradation of the parent compound as supposed to Day 0. Although similar 
results from the freezer samples should have been expected for all analytes that were stored 
in refrigerator, MBZP lost approximately 50% of its parent compound under refrigerator 
conditions. Likewise, MBZP was the least stable at room temperature where a 55% loss 
had occurred.    
 
 
Figure 2: Effect of different storage conditions on analyte stability over a 30-day trial. 
RT refers to room temperature. Temperature in freezer and fridge were at -20 ̊ C and 4 ̊ C 
respectively.   
  
In order to investigate possible analyte inferences, samples containing all synthetic 
piperazines at a concentration of 1000 ng/mL were also prepared and stored at multiple 
storage conditions for one month. Data on Figure 3 indicated that benzyl piperazines in 
BZP FBZP MBZP MeOPP pFPP mCPP DCPP TFMPP
Day 0 999 1168 1140 906 1142 1200 795 502
Day 30 (RT) 1105 787 503 1239 1201 1010 1061 499
Day 30 (Fridge) 949 902 606 767 917 973 705 385
Day 30 (Freezer) 1166 1295 1144 961 1073 979 876 686
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mixture were quite stable over time, but most phenyl piperazines showed moderate to 
severe degradation after only one month as shown on Figure 4-6. Additionally, the degree 
of loss for MeOPP, mCPP, DCPP and TFMPP in mixture was relatively smaller at room 
temperature than those in freezer. Also, the amount of pFPP remained in mixture after 30 
days was more or less the same among three storage conditions.  
 
 
 
Figure 3: Effect of different storage conditions on analyte interference and stability 
over a 30-day trial. RT refers to room temperature. Temperature in freezer and fridge were 
at -20 ̊ C and 4 ̊ C respectively.   
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Figure 4: Effect of different storage conditions on MeOPP in mixture overtime.  
 
 
Figure 5: Effect of different storage conditions on mCPP in mixture overtime. 
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Figure 6: Effect of different storage conditions on DCPP in mixture overtime. 
 
3.1.1 Isotopic Influence of DCPP on TFMPP 
 In the presence of two principle isotopes of chlorine-35 and chlorine-37, DCPP has 
a stable isotope with the same mass-to-charge ratio as TFMPP. Although TFMPP and this 
stable isotope of DCPP both generated a high intensity fragment ion at this specific mass-
to-charge ratio of 231, result of quantification of each analyte was still accurate even 
though both analytes might have coeluted. The crucial key justifying this interference issue 
is to keep the ratios between the internal standard and the calibrators as well as the ratios 
between the internal standard and unknown constant. In other words, the ratio of the DCPP 
isotope influence should always be kept constant.  
Day 0 Day 30 Day 91 Day 182 Day 270 Day 365
Room Temperature 986 654 648 426 15 31
Refrigerator 986 322 430 270 53 151
Freezer 986 358 221 100 433 218
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Figure 7: Virtual Q1 MS scan of TFMPP. This scan shows mass-to-charge ratios in Da 
on the x-axis and intensity in counts per second on the y-axis. Intensity level of the peak 
should be at about e^5 or above. 
 
 
Figure 8: Virtual Q1 MS scan of DCPP. This scan shows mass-to-charge ratios in Da on 
the x-axis and intensity in counts per second on the y-axis. Intensity level peak “231” 
should be at about e^5 or above; peak “232” should be at about e^3; peak “233” should be 
at about e^4 or above.  
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For example, if TFMPP and DCPP are both present in the calibrators and the mixed-
mode samples that consist of eight different piperazines used in this experiment, the result 
of quantification of each analyte present in mixture should be accurate. However, if the 
same set of calibrators (including TFMPP and DCPP) are used, the concentration of 
TFMPP alone in unknown sample will be underestimated (as shown on Figure 9 and 10) 
due to the absence of the “231” portion from DCPP. In this case, the ratio of the DCPP 
isotope was not kept constant. This explains the inconsistency of concentration of TFMPP 
on Day 0 of the 1-month and 6-month trials.  
 
Figure 9: Effect of different storage conditions on TFMPP in mixture on a 30-day 
trial under isotope interference. 
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Figure 10: Effect of different storage conditions on TFMPP in mixture overtime. 
 
3.2 Analysis of 3-Month Samples 
 Quantification of all samples were performed on both Day 0 and Day 91 using the 
same method. New calibration curves were generated on both Day 0 and Day 91. All % 
CV were within the standard range of 20%. According to Table 14, all R2 values were 
above the acceptable limit of 0.98. In this 91-day trial, two calibration curves were 
generated where the second one contained TFMPP only.  
Table 11: Average, standard deviation and percent coefficient of variation for analyte 
concentration in ng/mL on Day 0. All certified drug-free whole blood samples were 
fortified with the analytes at a concentration of 1000 ng/mL and run in triplicate. Analytes 
were prepared separately and in mixed-mode. The average concentration was calculated 
across these three runs. 
Analyte 
Average 
(ng/mL) Standard Deviation % CV 
 
Range (ng/mL) 
BZP 1017.21 51.29 5.04 973.11 – 1073.50 
FBZP 1092.87 132.69 12.14 1004.95 – 1245.50 
MBZP 1063.21 35.87 3.37 1035.76 – 1103.79 
Day 0 Day 91 Day 182 Day 270 Day 365
Room Temperature 1109 633 484 13 0
Refrigerator 1109 638 354 59 426
Freezer 1109 344 133 663 295
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MeOPP 1041.88 7.39 0.71 1035.76 – 1050.09 
pFPP 1027.77 34.75 3.38 988.38 – 1054.09 
mCPP 1025.55 7.00 0.68 1017.52 – 1030.39 
DCPP 1160.62 19.31 1.66 1138.36 – 1172.72 
TFMPP 1115.92 44.24 3.96 1066.81 – 1152.66 
MIX (BZP) 982.18 149.03 15.17 838.84 – 1136.32 
MIX (FBZP) 1023.27 132.43 12.94 894.67 – 1159.23 
MIX (MBZP) 1021.59 125.52 12.29 890.27 – 1140.38 
MIX (MeOPP) 922.58 29.67 3.22 892.99 – 952.33 
MIX (pFPP) 1003.93 26.51 2.64 980.11 – 1032.49 
MIX (mCPP) 1013.92 31.31 3.09 981.96 – 1044.54 
MIX (DCPP) 1036.60 12.44 1.20 1028.09 – 1050.87 
MIX (TFMPP) 1038.21 3.38 0.33 1035.19 – 1041.86 
 
 
Table 12: Average, standard deviation and percent coefficient of variation for analyte 
concentration in ng/mL on Day 91 at different storage conditions. All samples were 
run in triplicate. The average concentration was calculated across these three runs. RT 
refers to room temperature. 
 
Analyte / 
Storage Condition 
Averag 
(ng/mL) Standard Deviation % CV 
 
Range (ng/mL) 
BZP RT 934.90 110.27 11.79 807.60 – 1000.85 
BZP 4°C 1059.16 35.21 3.32 1025.17 – 1095.48 
BZP -20°C 1068.37 19.53 1.83 1046.83 – 1084.94 
     
FBZP RT 851.75 21.09 2.48 827.62 – 866.66 
FBZP 4°C 1017.92 13.31 1.31 1003.01 – 1028.62 
FBZP -20°C 908.15 5.87 0.65 901.63 – 913.01 
     
MBZP RT 1391.77 12.28 0.88 1380.41 – 1404.81 
MBZP 4°C 1130.29 36.20 3.20 1105.81 – 1171.88 
MBZP -20°C 1191.49 65.11 5.46 1118.61 – 1244.02 
     
MeOPP RT 542.09 19.94 3.68 520.16 – 559.15 
MeOPP 4°C 733.51 31.26 4.26 706.73 – 767.86 
MeOPP -20°C 645.49 18.74 2.90 633.43 – 667.08 
     
pFPP RT 513.79 10.09 1.96 502.27 – 521.03 
pFPP 4°C 744.71 22.15 2.97 719.13 – 758.15 
pFPP -20°C 910.21 41.96 4.61 864.18 – 946.32 
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mCPP RT 788.11 2.90 0.37 785.13 – 790.93 
mCPP 4°C 755.23 21.67 2.87 730.42 – 770.42 
mCPP -20°C 738.95 14.50 1.96 724.18 – 753.18 
     
DCPP RT 497.08 13.49 2.71 485.29 – 511.79 
DCPP 4°C 648.46 16.45 2.54 629.75 – 660.64 
DCPP -20°C 483.55 8.96 1.85 477.78 – 493.87 
     
TFMPP RT 686.02 12.80 1.87 675.00 – 700.06 
TFMPP 4°C 668.36 13.56 2.03 657.23 – 683.47 
TFMPP -20°C 580.24 13.60 2.34 565.76 – 592.75 
 
 
 
Table 13: Average, standard deviation and percent coefficient of variation for analyte 
concentration (in mixed-mode) in ng/mL on Day 91 at different storage conditions. 
All samples were run in triplicate. The average concentration was calculated across these 
three runs. RT refers to room temperature. 
 
Storage 
Condition Analyte  
Average 
(ng/mL) 
Standard 
Deviation % CV 
 
Range (ng/mL) 
MIX RT BZP 818.49 21.34 2.61 797.51 – 840.21 
MIX 4°C BZP 1036.19 124.88 12.05 909.06 – 1158.69 
MIX -20°C BZP 947.34 39.78 4.20 907.59 – 987.16 
      
MIX RT FBZP 859.85 9.42 1.10 848.98 – 865.71 
MIX 4°C FBZP 1028.58 51.75 5.03 969.61 – 1066.42 
MIX -20°C FBZP 937.74 31.75 3.39 915.32 – 974.07 
      
MIX RT MBZP 567.92 5.35 0.94 563.31 – 573.78 
MIX 4°C MBZP 1207.99 76.06 6.30 1123.56 – 1271.15 
MIX -20°C MBZP 1153.68 33.47 2.90 1121.30 – 1188.14 
      
MIX RT MeOPP 180.51 2.89 1.60 177.18 – 182.37 
MIX 4°C MeOPP 355.57 11.71 3.29 346.14 – 368.68 
MIX -20°C MeOPP 201.36 5.42 2.69 195.56 – 206.31 
      
MIX RT pFPP 401.66 7.98 1.99 392.49 – 407.04 
MIX 4°C pFPP 802.10 36.86 4.60 765.67 – 839.37 
MIX -20°C pFPP 638.09 20.32 3.19 614.66 – 650.99 
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MIX RT mCPP 528.15 5.70 1.08 521.61 – 532.03 
MIX 4°C mCPP 625.50 16.71 2.67 610.57 – 643.55 
MIX -20°C mCPP 334.02 9.31 2.79 327.15 – 344.62 
      
MIX RT DCPP 647.73 8.53 1.32 637.90 – 653.10  
MIX 4°C DCPP 429.72 11.27 2.62 416.76 – 437.24 
MIX -20°C DCPP 220.75 10.43 4.72 209.27 – 229.62 
      
MIX RT TFMPP 632.86 3.26 0.51 629.11 – 635.01 
MIX 4°C TFMPP 638.22 20.21 3.15 614.99 – 650.23 
MIX -20°C TFMPP 343.67 3.32 0.97 339.88 – 346.08 
 
 
 
Table 14: R2 values of each analyte ran on calibration curve on Day 0 and Day 91. 
 
 BZP FBZP MBZP MeOPP pFPP mCPP DCPP TFMPP 
R2 value 
(Day 0) 0.9963 0.9983 0.9933 0.9952 0.9970 0.9990 0.9985 0.9989 
R2 value 
(Day 91) 0.9985 0.9978 0.9872 0.9975 0.9937 0.9973 0.9865 0.9966 
 
 
 The concentration level on Day 91 among three benzyl piperazines that were kept 
frozen demonstrated minimal variation of less than 15% loss as compared to Day 0. In 
contrast, phenyl piperazines that were stored in freezer had moderate degradations 
especially DCPP and TFMPP, which were only left with 42% and 52% of its parent 
compound, respectively. Furthermore, all phenyl samples kept at 4 ̊ C experienced an 
approximately 30 to 40% loss since Day 0 while BZP, FBZP and MBZP seemed to be 
relatively stable. Unlike the result obtained from the 1-month trial, MBZP did not degrade 
much under both room temperature and 4 ̊ C. As expected, the degree of loss of all synthetic 
piperazines stored at room temperature was larger than those which were kept at 4 ̊ C or -
20 ̊ C except for MBZP, mCPP and TFMPP. 
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 While BZP and FBZP showed very little degradation when mixed with other 
analytes, MBZP had a 45% loss when kept at room temperature in mixed-mode. Although 
pFPP in mixed-mode experienced the greatest loss of analyte at room temperature which 
was contradictory to the pattern observed from the 1-month trial, result of mCPP, DCPP 
and TFMPP in mixed-mode quantitated on Day 91 were still consistent with it. This was 
because degree of loss of these three particular piperazines stored in freezer was 
significantly larger than those kept in ambient temperature. Additionally, there was a 
dramatic loss of MeOPP in mixed-mode under all storage conditions: less than 20% of 
MeOPP was recovered in whole blood after 91 days at room temperature while the sample 
also lost 60 to 80% of its parent analyte at the other two conditions.  
 
 
 
Figure 11: Effect of different storage conditions on analyte interference and stability 
over a 91-day trial. RT refers to room temperature. Temperature in freezer and fridge were 
at -20 ̊ C and 4 ̊ C respectively. Noted that severe degradation was observed in MeOPP 
after 91 days. 
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To overcome the isotope interference in this trial, a separate calibration curve was 
prepared with only TFMPP as the calibrators on Day 0. This would eliminate the influence 
of all mass-to-charge ratios of DCPP so that a reliable quantification of TFMPP can be 
made. 
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3.3 Analysis of 6-Month Samples 
 
New calibration curves were generated for quantification analyses on both Day 0 
and Day 182. According to Table 18, all R2 values were above the acceptable limit of 0.98. 
Although almost every analyte fell within the % CV acceptable range of 20%, MeOPP that 
was stored under -20 ̊ C, mCPP that was kept at 4 ̊ C, DCPP stored at both room 
temperature and -20 ̊ C as well as DCPP in mixed-mode that was stored at -20 ̊ C had all 
exceeded the 20% limit.  
Table 15: Average, standard deviation and percent coefficient of variation for analyte 
concentration in ng/mL on Day 0. All certified drug-free whole blood samples were 
fortified with the analytes at a concentration of 1000 ng/mL and run in triplicate. Analytes 
were prepared separately and in mixed-mode. The average concentration was calculated 
across these three runs. 
 
Analyte 
Average 
(ng/mL) Standard Deviation % CV 
 
Range (ng/mL) 
BZP 1000.99 40.51 4.05 970.45 – 1046.94 
FBZP 1037.91 36.95 3.56 1010.24 – 1079.87 
MBZP 1044.95 36.52 3.50 1006.74 – 1079.51 
MeOPP 727.61 11.19 1.54 720.68 – 740.52 
pFPP 806.31 2.36 0.29 804.06 – 808.78 
mCPP 1012.62 6.59 0.65 1005.10 – 1017.41 
DCPP 996.67 12.24 1.23 991.74 – 1010.60 
TFMPP 548.59 4.22 0.77 544.65 – 553.05 
MIX (BZP) 1107.67 53.24 4.81 1046.2 – 1138.49 
MIX (FBZP) 1169.57 27.35 2.34 1141.98 – 1196.68 
MIX (MBZP) 1066.12 46.43 4.35 1014.12 – 1103.43 
MIX (MeOPP) 1242.55 7.64 0.61 1237.53 – 1251.34 
MIX (pFPP) 1204.68 6.67 0.55 1197.52 – 1210.73 
MIX (mCPP) 1061.60 5.87 0.55 1055.56 – 1067.29 
MIX (DCPP) 1038.57 20.43 1.97 1018.89 – 1059.67 
MIX (TFMPP) 1178.65 7.84 0.66 1173.84 – 1187.69 
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Table 16: Average, standard deviation and percent coefficient of variation for analyte 
concentration in ng/mL on Day 182 at different storage conditions. All samples were 
run in triplicate. The average concentration was calculated across these three runs. RT 
refers to room temperature. 
 
Analyte / 
Storage Condition 
Average 
(ng/mL) Standard Deviation % CV  
 
Range (ng/mL) 
BZP RT 253.42 0.94 0.37 252.53 – 254.40 
BZP 4°C 240.88 3.01 1.25 237.45 – 243.07 
BZP -20°C 443.01 4.11 0.93 439.13 – 447.33 
     
FBZP RT 67.76 1.20 1.77 66.63 – 69.02 
FBZP 4°C 81.39 1.49 1.83 80.26 – 83.08 
FBZP -20°C 317.75 7.57 2.38 311.63 – 326.21 
     
MBZP RT 1144.30 13.53 1.18 1128.98 – 1154.64 
MBZP 4°C 959.84 32.84 3.42 922.76 – 985.26 
MBZP -20°C 1189.62 77.19 6.49 1100.91 – 1241.49 
     
MeOPP RT 0.00 0.00 0.00 0.00 
MeOPP 4°C 0.00 0.00 0.00 0.00 
MeOPP -20°C 3.42 5.93 173.21 0.00 – 10.27 
     
pFPP RT 76.25 7.13 9.36 70.12 – 84.09 
pFPP 4°C 17.33 0.97 5.62 16.61 – 18.44 
pFPP -20°C 105.61 10.33 9.78 98.69 – 117.49 
     
mCPP RT 9.84 0.12 1.25 9.75 – 9.98 
mCPP 4°C 15.59 3.15 20.20 13.24 – 19.17 
mCPP -20°C 56.39 1.16 2.06 55.15 – 57.44 
     
DCPP RT 13.19 2.92 22.13 9.84 – 15.15 
DCPP 4°C 16.64 1.54 9.27 15.45 – 18.38 
DCPP -20°C 78.14 17.14 21.94 65.71 – 97.70 
     
TFMPP RT 13.33 0.91 6.82 12.56 – 14.33 
TFMPP 4°C 15.72 1.40 8.88 14.77 – 17.32 
TFMPP -20°C 63.57 4.22 6.63 58.72 – 66.39 
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Table 17: Average, standard deviation and percent coefficient of variation for analyte 
concentration (in mixed-mode) in ng/mL on Day 182 at different storage conditions. 
All samples were run in triplicate. The average concentration was calculated across these 
three runs. RT refers to room temperature. 
 
Storage 
Condition Analyte 
Average 
(ng/mL) 
Standard 
Deviation % CV 
 
Range (ng/mL) 
MIX RT BZP 1017.58 23.11 2.27 990.92 – 1032.01 
MIX 4°C BZP 960.53 11.52 1.20 948.21 – 971.04 
MIX -20°C BZP 912.41 6.47 0.71 905.21 – 917.75 
      
MIX RT FBZP 870.14 28.87 3.32 842.83 – 900.35 
MIX 4°C FBZP 748.80 20.44 2.73 728.83 – 769.67 
MIX -20°C FBZP 690.55 16.60 2.40 674.57 – 707.71 
      
MIX RT MBZP 948.06 5.71 0.60 943.09 – 954.30 
MIX 4°C MBZP 922.26 41.09 4.45 893.39 – 969.29 
MIX -20°C MBZP 992.61 42.67 4.30 959.61 – 1040.80 
      
MIX RT MeOPP 320.15 4.26 1.33 315.49 – 323.85 
MIX 4°C MeOPP 546.49 9.44 1.73 536.27 – 554.89 
MIX -20°C MeOPP 74.01 5.79 7.83 70.36 – 80.69 
      
MIX RT pFPP 901.84 26.14 2.90 877.31 – 929.34 
MIX 4°C pFPP 1106.89 45.09 4.07 1066.69 – 1155.65 
MIX -20°C pFPP 625.25 36.56 5.85 583.14 – 648.80 
      
MIX RT mCPP 484.10 7.67 1.58 476.78 – 492.08 
MIX 4°C mCPP 376.94 5.41 1.44 370.73 – 380.62 
MIX -20°C mCPP 124.02 6.59 5.31 116.79 – 129.68 
      
MIX RT DCPP 425.92 7.27 1.71 419.56 – 433.85 
MIX 4°C DCPP 270.05 9.74 3.61 258.85 – 276.54 
MIX -20°C DCPP 99.53 22.56 22.67 73.82 – 116.03 
      
MIX RT TFMPP 484.28 6.29 1.30 477.08 – 488.69 
MIX 4°C TFMPP 353.65 0.62 0.18 353.30 – 354.37 
MIX -20°C TFMPP 133.15 1.03 0.78 131.99 – 133.99 
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Table 18: R2 values of each analyte ran on calibration curve on Day 0 and Day 182. 
 
 BZP FBZP MBZP MeOPP pFPP mCPP DCPP TFMPP 
R2 value 
(Day 0) 0.9963 0.9944 0.9977 0.9964 0.9878 0.9936 0.9951 0.9932 
R2 value 
(Day 182) 0.9926 0.9915 0.9848 0.9914 0.9847 0.9983 0.9940 0.9995 
 
Figure 13-16 suggested that most piperazines in blood experienced the highest rate 
of degradation between Day 91 and 182; the amount loss was significantly larger than those 
shown on Day 30 and Day 91. When stored at -20°C, all three benzyl piperazines had a 
smaller degree of loss as opposed to all of the phenyl piperazines; this was consistent with 
the degradation pattern observed from the 1-month and the 3-month trial. Under both room 
temperature and 4°C, the degree of degradation of BZP and FBZP revealed a 75% and 90% 
loss respectively, and showed almost no differences indicating stability at a particular 
storage condition over another. However, MBZP was comparably stable under all storage 
conditions where more than 90% of its parent compound was still detected after six months. 
In general, all phenyl piperazines were slightly more stable at -20°C because only 
approximately 2% of their parent compounds were still available under room temperature 
and 4°C. Among all phenyl piperazines, MeOPP experienced the largest degradation in 
which only approximately 3 ng/mL of its parent compound remained in the blood sample 
when stored at -20°C. No MeOPP was detected under room temperature or 4°C. In addition 
to phenyl piperazines, pFPP was more stable when stored in freezer and room temperature 
instead of refrigerating condition.   
48 
 
 
Figure 13: Effect of different storage conditions on FBZP overtime. 
 
Figure 14: Effect of different storage conditions on pFPP overtime. 
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Figure 15: Effect of different storage conditions on MeOPP overtime. 
 
Figure 16: Effect of different storage conditions on DCPP overtime. 
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FBZP were found to be the most stable under room temperature when mixed with other 
piperzines. Moreover, MBZP had the least amount of loss out of all piperzines under the 
influence of analyte interferences. In contrast, all phenyl piperazines, except for pFPP, lost 
more than 50% of their parent analytes at every storage condition. In addition, MeOPP, 
pFPP, mCPP, DCPP and TFMPP were all clearly experiencing a significant loss over time 
at -20 ̊ C; and this was consistent with other trials where a shorter period of storage time 
was implemented in which all of the non-benzyl piperazines were relatively more stable 
under room temperature. Nonetheless, it should be pointed out that only 74 ng/mL of 
MeOPP remained in blood when kept under -20 ̊ C in mixed-mode. This particular analyte 
demonstrated a degree of degradation of more than 95% loss over a 182-day trial under 
freezing condition in mixed-mode.   
To further support illustrating data analysis, a representative total ion 
chromatogram of a 2000ng/mL calibrator and a representative calibration curve are shown 
on Figure 17 and Figure 18.  
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Figure 17: Total ion chromatogram of a 2000 ng/mL calibrator in blood on Day 0 of 
the 6-month trial.  The x-axis is time ranging from 0-6.5 min and the y-axis is intensity 
measured in counts per second (cps) ranging from 0-4.1e6. Analytes elute at the following 
retention times: BZP-d7 at 3.74 min, BZP at 3.85 min, FBZP at 4.53 min, MBZP at 4.71 
min, MeOPP at 5.10 min, pFPP at 5.34 min, mCPP-d8 at 5.80 min, mCPP at 5.81 min, 
DCPP at 6.12 min, TFMPP at 6.15 min, and TFMPP-d4 at 6.16 min. 
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3.4 Analysis of 9-Month Samples 
On Day 270, a set of new calibration curves were prepared to estimate and 
quantitate the amount of piperazines left in blood. According to Table 21, all R2 values 
were above the acceptable limit of 0.98.  
Table 19: Average, standard deviation and percent coefficient of variation for analyte 
concentration in ng/mL on Day 270 at different storage conditions. All samples were 
run in triplicate. The average concentration was calculated across these three runs. RT 
refers to room temperature. 
 
Analyte / 
Storage Condition 
Average 
(ng/mL) 
 
Standard Deviation 
 
% CV 
 
Range (ng/mL) 
BZP RT 600.41 10.58 1.76 590.36 – 611.45 
BZP 4°C 671.34 40.60 6.05 630.82 – 712.01 
BZP -20°C 576.30 31.97 5.55 545.85 – 609.60     
 
FBZP RT 63.75 1.03 1.61 63.08 – 64.93 
FBZP 4°C 81.48 5.87 7.20 75.38 – 87.09 
FBZP -20°C 331.61 9.39 2.83 320.98 – 338.80     
 
MBZP RT 1223.00 11.17 0.91 1210.14 – 1230.32 
MBZP 4°C 1530.80 50.88 3.32 1486.61 – 1586.42 
MBZP -20°C 1262.52 16.33 1.29 1244.10 – 1275.24     
 
MeOPP RT 63.06 17.85 28.31 51.15 – 83.58 
MeOPP 4°C 143.96 40.22 27.94 117.15 – 190.21 
MeOPP -20°C 179.06 40.41 22.57 132.70 – 206.77     
 
pFPP RT 167.07 46.91 28.08 139.24 – 221.23 
pFPP 4°C 236.47 62.92 26.61 199.48 – 309.12 
pFPP -20°C 172.96 42.75 24.72 124.09 – 203.45     
 
mCPP RT 26.12 0.45 1.73 25.60 – 26.43 
mCPP 4°C 69.02 3.07 4.45 66.47 – 72.43 
mCPP -20°C 151.02 5.46 3.61 147.58 – 157.31     
 
DCPP RT 9.10 1.50 16.49 8.23 – 10.83 
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DCPP 4°C 26.52 9.26 34.92 19.71 – 37.07 
DCPP -20°C 106.07 22.58 21.28 80.10 – 120.98     
 
TFMPP RT 0.71 1.22 173.21 0.00 – 2.12 
TFMPP 4°C 22.46 30.63 136.38 4.63 – 57.83 
TFMPP -20°C 88.80 34.47 38.81 60.68 – 127.25 
 
 
Table 20: Average, standard deviation and percent coefficient of variation for analyte 
concentration (in mixed-mode) in ng/mL on Day 270 at different storage conditions. 
All samples were run in triplicate. The average concentration was calculated across these 
three runs. RT refers to room temperature. 
 
Storage 
Condition 
Analyte Average 
(ng/mL) 
Standard 
Deviation 
% CV Range (ng/mL) 
MIX RT BZP 666.34 24.07 3.61 643.32 – 691.35 
MIX 4°C BZP 1056.03 21.99 2.08 1041.38 – 1081.31 
MIX -20°C BZP 1150.42 43.97 3.82 1117.84 – 1200.44      
 
MIX RT FBZP 248.16 17.36 7.00 229.11 – 263.09 
MIX 4°C FBZP 591.88 10.65 1.80 579.59 – 598.29 
MIX -20°C FBZP 755.16 24.23 3.21 728.98 – 776.78      
 
MIX RT MBZP 1015.99 38.53 3.79 973.52 – 1048.72 
MIX 4°C MBZP 1420.35 23.77 1.67 1393.60 – 1439.06 
MIX -20°C MBZP 1213.90 37.52 3.09 1170.61 – 1237.14      
 
MIX RT MeOPP 144.78 2.34 1.62 143.19 – 147.47 
MIX 4°C MeOPP 383.79 104.29 27.17 312.57 – 502.50 
MIX -20°C MeOPP 597.88 103.62 17.33 510.90 – 712.52      
 
MIX RT pFPP 131.94 32.37 24.53 111.28 – 169.25 
MIX 4°C pFPP 362.36 90.71 25.03 296.89 – 465.90 
MIX -20°C pFPP 659.38 132.56 20.10 552.67 – 808.77      
 
MIX RT mCPP 34.36 1.49 4.35 32.94 – 35.92 
MIX 4°C mCPP 131.46 6.54 4.97 124.89 – 137.96 
MIX -20°C mCPP 801.51 21.91 2.73 781.27 – 824.77      
 
MIX RT DCPP 15.00 3.58 23.88 12.82 – 19.13 
MIX 4°C DCPP 53.35 11.72 21.97 44.00 – 66.50 
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MIX -20°C DCPP 433.09 4.88 1.13 427.52 – 436.57      
 
MIX RT TFMPP 12.83 11.52 89.78 5.82 – 26.12 
MIX 4°C TFMPP 59.17 6.26 10.58 55.34 – 66.39 
MIX -20°C TFMPP 663.43 8.02 1.21 657.98 – 672.64 
 
 
Table 21: R2 values of each analyte ran on calibration curve on Day 270. 
 
 BZP FBZP MBZP MeOPP pFPP mCPP DCPP TFMPP 
R2 value 
(Day 270) 0.9993 0.9993 0.9814 0.9973 0.9966 0.9986 0.9952 0.9977 
 
 Similar to the degradation pattern observed on Day 91 and Day 182, all benzyl 
piperazines were comparatively more stable than phenyl piperazines in blood. Although 
data on Day 270 showed that MBZP perhaps was the most stable compound among all 
piperazines, the amount of MBZP remained in blood after storing in a refrigerator for nine 
months was detected at an exceptionally high concentration of 1530 ng/mL. Since all 
samples were spiked at a designated initial concentration of 1000 ng/mL, the presence of 
MBZP as a metabolite from other piperazines or compounds that are structurally-related to 
MBZP in the same matrix could not be ruled out as the source of this outlier. Overall, 
MeOPP, mCPP, DCPP and TFMPP were determined to be the most stable in blood at -20 ̊ 
C, followed by 4 ̊ C and room temperature.  
 While the degree of degradation of BZP and MBZP were smaller in mixed-mode 
samples, there was a moderate loss of FBZP at -20 ̊ C and 4 ̊ C.  Table 20 also indicated 
that FBZP in blood was very unstable at room temperature under mixed-mode. Unlike the 
findings obtained from Day 30, 91 and 182, all phenyl piperazine derivatives were the most 
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stable in freezer. For example, more than 80% of mCPP was still detected on Day 270 
when it was stored at -20 ̊ C under mixed-mode condition.  
 
3.4.1 Matrix Interference 
As shown on Table 20, MBZP in mixed-mode sample which was originally spiked 
at 1000 ng/mL had reached 1420 ng/mL after storing at 4 ̊ C for 270 days. Since slight 
coagulation was observed in some samples after nine months, matrix interference could 
not be excluded as one of the causes of this exceptionally high level of MBZP. This is 
because blood coagulation could be a result of alternation of physiochemical properties 
such as viscosity and surface tension. Although limited information is currently available 
on synthetic piperazines’ metabolic pathways, the excess amount of MBZP quantified in 
this trial could be a result of the presence of active metabolites that share the same mass-
to-charge ratio with MBZP. Also, the possibility of having MBZP as the metabolite derived 
from other piperazines under mixed-mode could confound the validity of this result as well.  
 
3.5 Analysis of 12-Month Samples 
 
To quantitate the amount of synthetic piperazines left in blood after storing for 365 
days, a set of new calibration curves were prepared. All R2 values were above the 
acceptable limit of 0.98 (Table 24). All % CV were within the 20% limit range.  
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Table 22: Average, standard deviation and percent coefficient of variation for analyte 
concentration in ng/mL on Day 365 at different storage conditions. All samples were 
run in triplicate. The average concentration was calculated across these three runs. RT 
refers to room temperature. 
 
Analyte / 
Storage Condition 
Average 
(ng/mL) 
 
Standard Deviation 
 
% CV 
 
Range (ng/mL) 
BZP RT 284.83 13.00 4.56 269.94 – 293.85 
BZP 4°C 585.98 6.80 1.16 581.91 – 593.83 
BZP -20°C 662.86 22.46 3.39 640.48 – 685.41     
 
FBZP RT 63.72 3.62 5.68 60.91 – 67.80 
FBZP 4°C 166.41 9.44 5.67 155.52 – 172.03 
FBZP -20°C 442.59 5.57 1.26 436.68 – 447.73     
 
MBZP RT 874.87 31.06 3.55 843.32 – 905.41 
MBZP 4°C 713.65 49.57 6.95 673.20 – 768.96 
MBZP -20°C 966.52 69.82 7.22 917.80 – 1046.51     
 
MeOPP RT 398.36 4.84 1.21 394.67 – 403.83 
MeOPP 4°C 474.92 5.07 1.07 469.10 – 478.31 
MeOPP -20°C 366.65 5.58 1.52 360.49 – 371.34     
 
pFPP RT 314.91 3.86 1.22 311.80 – 319.22 
pFPP 4°C 711.98 1.97 0.28 710.04 – 713.99 
pFPP -20°C 590.29 21.05 3.57 567.86 – 609.61     
 
mCPP RT 75.59 2.19 2.90 73.14 – 77.36 
mCPP 4°C 621.57 4.15 0.67 616.79 – 624.31 
mCPP -20°C 408.93 17.93 4.38 398.15 – 429.63     
 
DCPP RT 20.07 1.74 8.67 18.70 – 22.03 
DCPP 4°C 79.98 2.95 3.69 77.79 – 83.34 
DCPP -20°C 283.65 7.92 2.79 275.08 – 290.70     
 
TFMPP RT 73.32 4.34 5.92 68.89 – 77.57 
TFMPP 4°C 420.73 4.87 1.16 416.98 – 426.23 
TFMPP -20°C 343.50 13.00 3.78 333.01 – 358.04 
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Table 23: Average, standard deviation and percent coefficient of variation for analyte 
concentration (in mixed-mode) in ng/mL on Day 365 at different storage conditions. 
All samples were run in triplicate. The average concentration was calculated across these 
three runs. RT refers to room temperature. 
Storage 
Condition 
 
Analyte 
Average 
(ng/mL) 
Standard 
Deviation 
 
% CV 
 
Range (ng/mL) 
MIX RT BZP 819.04 25.49 3.11 790.08 – 838.10 
MIX 4°C BZP 841.29 34.43 4.09 803.83 – 871.55 
MIX -20°C BZP 851.54 17.90 2.10 832.67 – 868.27      
 
MIX RT FBZP 428.13 18.51 4.32 407.44 – 443.14 
MIX 4°C FBZP 533.04 40.65 7.63 487.67 – 566.15 
MIX -20°C FBZP 709.08 46.53 6.56 663.66 – 756.64      
 
MIX RT MBZP 839.11 52.80 6.29 787.67 – 893.16 
MIX 4°C MBZP 955.15 100.15 10.49 849.42 – 1048.59 
MIX -20°C MBZP 1008.18 93.28 9.25 907.27 – 1091.26      
 
MIX RT MeOPP 2.62 0.12 4.62 2.55 – 2.76 
MIX 4°C MeOPP 628.54 16.34 2.60 610.48 – 642.30 
MIX -20°C MeOPP 343.71 2.10 0.61 341.42 – 345.55      
 
MIX RT pFPP 0.00 0.00 0.00 0.00-0.00 
MIX 4°C pFPP 1015.68 45.69 4.50 963.61 – 1049.09 
MIX -20°C pFPP 553.10 1.81 0.33 551.46 – 555.03      
 
MIX RT mCPP 0.00 0.00 0.00 0.00 – 0.00 
MIX 4°C mCPP 903.02 41.98 4.65 859.23 – 942.91 
MIX -20°C mCPP 337.90 2.91 0.86 336.15 – 341.26      
 
MIX RT DCPP 31.20 2.16 6.93 29.10 – 33.43 
MIX 4°C DCPP 150.89 8.31 5.50 144.24 – 160.20 
MIX -20°C DCPP 217.99 10.70 4.91 205.76 – 225.68      
 
MIX RT TFMPP 0.00 0.00 0.00 0.00 – 0.00 
MIX 4°C TFMPP 426.00 10.19 2.39 414.71 – 434.51 
MIX -20°C TFMPP790.0 294.50 6.79 2.31 288.45 – 301.84 
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Table 24: R2 values of each analyte ran on calibration curve on Day 365. 
 
 BZP FBZP MBZP MeOPP pFPP mCPP DCPP TFMPP 
R2 value 
(Day 365) 0.9976 0.9993 0.9865 0.9953 0.9995 0.9993 0.9970 0.9998 
 
 Analytes had the smallest degrees of loss when stored at -20°C, which was 
consistent with the hypothesis that synthetic piperazines should be more stable in blood 
under freezing condition. In addition, MBZP was found to be extremely stable regardless 
of storage conditions; more than 70% of its parent analyte was still detected after 12 
months. Overall, each phenyl piperazine, except for DCPP, lost most of its analyte at 4°C 
instead of -20°C. Furthermore, mCPP, DCPP and TFMPP exhibited the largest degradation 
in which only ~10% of their parent analytes were left in blood when stored at room 
temperature.  
 Similar to all of the other trials, benzyl piperazines in mix-mode were significantly 
more stable than phenyl piperazines. However, it was clear that all phenyl piperazines had 
a dramatic decline in concentration level after storing them for 12 months at room 
temperature under mix-mode. For example, MeOPP, pFPP, mCPP and TFMPP were not 
detectable after 365 days. As a result, it is highly recommended to store matrices containing 
synthetic piperazines at an appropriate storage condition rather than at room temperature. 
This might help to retain more of the compound(s) when samples are retained for extended 
periods of time.  
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Figure 19: Effect of different storage conditions on mCPP overtime. 
 
 
Figure 20: Effect of different storage conditions on TFMPP overtime. 
 Moreover, pFPP, MeOPP, mCPP and TFMPP had a resurgence on analyte 
concentration level after keeping them for 12 months as shown in Figure 14, 15, 19 and 20. 
The phenomenon could be a result of: the presence of active metabolite sharing the same 
mass-to-charge ratio with its parent compound; having compounds that owned similar 
structures; or having the identical molecular weight with the original piperazines spiked on 
Day 0. This might falsely mislead the way how the MS would detect designated ions and 
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affect the precision of the whole quantification process where specificity could have been 
impacted.  
3.6 Background Noise  
Although a higher background noise at the end of the column separation was 
expected for this method, multiple double blanks and solvent blanks between 0 and 5.5 
minutes had a relatively high background noise intensity after a new roughing pump had 
been replaced on the instrument as part of the annual maintenance.  As shown in Figure 
22, a normal baseline should be between 0 and 1000cps. However in Figure 21, the 
background noise has reached approximately 2000cps for one particular analyte. 
According to the SWGTOX guidelines, the chromatogram is acceptable as long as the 
response (peak area) of the analyte’s lower LOQ is greater than the background noise. 
Since all lower LOQ (defined as 25% of the LOQ) of each analyte had a response greater 
than the highest baseline noise of about 4000cps, the background noise issue was justified 
and could be ignored. Thus, the concentration of each analyte in unknown samples was 
accurately quantified.  
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Figure 21: Total ion chromatogram (with high background noise at about 2000cps) 
of a double blank on Day 0 of the 3-month trial. This scan shows mass-to-charge ratios 
in Da on the x-axis and intensity in counts per second on the y-axis. 
 
 
Figure 22: Total ion chromatogram (with normal background noise between 500 and 
1000cps) of a solvent blank on Day 0 of the 6-month trial. This scan shows mass-to-
charge ratios in Da on the x-axis and intensity in counts per second on the y-axis.  
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4. CONCLUSION 
4.1 Summary of Findings  
The use of solid phase extraction as a sample preparation technique was proven to 
be successful to obtain analytes of interest by removing matrices and unwanted 
components from the sample. Not only the quantification of synthetic piperazines using a 
UFLC-MS/MS system was robust and reliable, but also the method utilized in this project 
including equilibrations had a quick total run time of 11.5 minutes. All calibrations curves 
exhibited an R2 value above 0.98 and had met the criteria according to the SWGTOX 
guideline.  
Data on this stability investigation revealed that BZP, MBZP and FBZP were 
generally more stable than all other phenyl piperazines over time under all storage 
conditions, in which MBZP was extremely stable and still had at least 70% left after 12 
months. Most data, if not all, showed a smaller degree of degradation if proper storage 
conditions were maintained that is when samples were kept in either a refrigerator or a 
freezer. In contrast, storing samples at room temperature should be avoided because of 
detrimental impacts on stability of piperazine compounds. This information is very 
valuable when analyzing data for postmortem specimens that are collected from a 
decomposed body or a body that is found in an exceptionally warm environment. For crime 
laboratories that are facing backlog situations, it is recommended that specimen containing 
synthetic piperazines should be kept frozen or refrigerated even for time period as short as 
30 days or less. However, they should not be stored for more than six months because 
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phenyl piperazines are more susceptible to lose all parent compounds after six months 
regardless of storage conditions.  
4.2 Analyte and Matrix Interference  
Similarly, all benzyl piperazines were comparably more stable than phenyl 
piperazines in mixed-mode under all storage conditions. For this reason, it was determined 
that the stability of BZP, MBZP and FBZP were less likely to be affected by analyte 
interferences in blood over time. However, all phenyl piperazines including TFMPP, 
DCPP, mCPP, pFPP and MeOPP experienced severe degradation after only 30 days. In 
addition, they had lost more than 50% of their initial concentration after three months. 
Phenyl piperazines when mixed with other derivatives appeared to be more stable 
at 4 ̊ C or even at room temperature as opposed to -20 ̊ C. Data from Day 91 and 182 
indicated that DCPP and TFMPP under mixed-mode were consistently more stable at room 
temperature. Although this was contradicting the hypothesis that synthetic piperazines in 
biological specimens are more likely to degrade at a slower rate when stored in a freezer 
or refrigerator, this piece of information is very useful for laboratories that have limited 
freezer storage; this is because detectable levels of analytes in whole blood might still be 
able to be quantified after three to six months without freezing. However, the exact stability 
pattern of phenyl piperazines when mixed together could not be determined from this data 
set alone due to discrepancies observed on Day 91 and 270.  
The high level of MBZP concentration quantitated on Day 270 could be a result of 
matrix interference because of slight coagulation observed in some blood samples. In 
addition, the presence of metabolites derived from other piperazines or the presence of 
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structurally-related compounds that shared the same mass-to-charge ratio with the target 
analyte could have contributed to the late peak increase of mCPP, DCPP and MeOPP under 
mixed-mode. Thus, this result emphasized that further work is needed to explore the most 
stable storage condition and necessary precautions for specimens containing more than one 
synthetic piperazines in order to ensure minimal degradation. 
 
4.3 DCPP and TFMPP 
For cases that involve the mixture of BZP and other piperazine drugs such as 
TFMPP that shares certain pharmacodynamic traits with MDMA, data suggested that both 
of these piperazines will still be detectable after three months or even a longer period of 
time that can be encountered in backlog situations. Moreover, if DCPP and TFMPP are 
both present in whole blood specimen, a separate calibration curve containing only TFMPP 
is required in order to obtain an accurate quantitative result that reflects the actual 
concentration of TFMPP in blood. Another possible solution to avoid the DCPP influence 
on TFMPP is to optimize this current method so that both analytes will have their individual 
discrete mass-to-charge ratio values.   
 
4.4 Future Direction 
As the number, categories and analogs of designer drugs continues to emerge, the 
stability of synthetic piperazines is crucial in terms of data analyses for forensic casework. 
This research project has shown a solid method to examine how quickly or slowly synthetic 
piperazines degrade in blood at each storage condition. For future research, it is also 
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important to evaluate the number of freeze-thaw cycles on each specimen in order to 
minimize the effect of non-metabolic degradation. At practical levels, the stability of 
piperazines when stored at -60 ̊C to -80 ̊C should also be investigated to support the 
hypothesis that lower temperature freezing conditions are believed to be the most stable 
environment for piperazines in blood.  
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APPENDIX A: BAR GRAPH / LINE GRAPH DATA 
 
 
Figure A: Effect of different storage conditions on analyte stability over a 91-day trial. 
RT refers to room temperature. Temperature in freezer and fridge were at -20 ̊ C and 4 ̊ C 
respectively. 
 
 
 
Figure B: Effect of different storage conditions on analyte stability over a 182-day 
trial. RT refers to room temperature. Temperature in freezer and fridge were at -20 ̊ C and 
4 ̊ C respectively. 
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Figure C: Effect of different storage conditions on analyte interference and stability 
over a 182-day trial. RT refers to room temperature. Temperature in freezer and fridge 
were at -20 ̊ C and 4 ̊ C respectively. 
 
 
 
Figure D: Effect of different storage conditions on analyte stability over a 270-day 
trial. RT refers to room temperature. Temperature in freezer and fridge were at -20 ̊ C and 
4 ̊ C respectively. 
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Figure E: Effect of different storage conditions on analyte interference and stability 
over a 270-day trial. RT refers to room temperature. Temperature in freezer and fridge 
were at -20 ̊ C and 4 ̊ C respectively. 
 
 
Figure F: Effect of different storage conditions on BZP overtime. 
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Figure G: Effect of different storage conditions on BZP in mixture overtime. 
 
 
Figure H: Effect of different storage conditions on MBZP overtime. 
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Figure I: Effect of different storage conditions on MBZP in mixture overtime. 
 
 
Figure J: Effect of different storage conditions on FBZP in mixture overtime. 
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Figure K: Effect of different storage conditions on pFPP in mixture overtime. 
 
 
Figure L: Effect of different storage conditions on TFMPP overtime. 
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APPENDIX B: CHROMATOGRAPHIC DATA 
 
 
 
Figure A: Total ion chromatogram of certified drug-free whole blood (Lot#: B1027) 
on Day 30 of the 1-month trial. This scan shows mass-to-charge ratios in Da on the x-
axis and intensity in counts per second on the y-axis. 
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Figure B: Total ion chromatogram of certified drug-free whole blood (Lot#: B1086) 
on Day 0 of the 1-month trial. This scan shows mass-to-charge ratios in Da on the x-axis 
and intensity in counts per second on the y-axis. 
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